Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc
Journal website https://jmc.elmerpub.com

Case Report

Volume 17, Number 4, April 2026, pages 146-152

High-Risk Chronic Lymphocytic Leukemia in a Young Adult Treated With Reduced-Dosage, Fixed-Duration Ibrutinib and Venetoclax

Figures

↓  Figure 1. (a) Mature lymphocytes (red arrows), and prolymphocyte (yellow arrow). (b) Basket cell/smudge cell (black arrow).
Figure 1.
↓  Figure 2. (a) Hypercellular bone marrow partially effaced by a population of atypical round cells that comprise approximately 80–90% of the marrow cellularity (arrows). The atypical cells show strong membranous staining for CD20 (b), moderate-to-strong membranous staining for CD5 (c) and are negative for cyclin-D1 (d). Taken together, the immuno-morphologic features support involvement by chronic lymphocytic leukemia (arrows).
Figure 2.
↓  Figure 3. Temporal evolution of hemoglobin and platelet counts in relation to blood transfusion and initiation of treatment with ibrutinib monotherapy, followed by ibrutinib and venetoclax combination. PRBC: packed red blood cell
Figure 3.